This clinical trial is focused on studying the long-term effects of a medication called ACP-204 in adults who have a condition known as Alzheimer’s Disease Psychosis. Alzheimer’s Disease Psychosis is a condition where individuals with Alzheimer’s disease experience symptoms such as hallucinations or delusions. The medication being tested, ACP-204, is taken in the form of a capsule and is designed to help manage these symptoms.

The purpose of this study is to evaluate how safe and tolerable ACP-204 is when used over a long period, specifically 52 weeks. Participants in the study will take the medication orally, meaning they will swallow the capsule. The study will monitor participants for any side effects or adverse reactions to the medication during this time. This is an extension study, meaning it follows up on a previous study to gather more information about the medication’s long-term use.

Throughout the study, participants will be regularly assessed to ensure their well-being and to track any changes in their condition. The study aims to provide valuable information on the safety of ACP-204 for individuals with Alzheimer’s Disease Psychosis, contributing to a better understanding of how this medication can be used in managing the condition over an extended period.